TIGIT-mediated signaling is known to suppress an array of anti-cancer immune cells and has been associated with poor prognosis in a variety of tumor types.
Domvanalimab is designed to promote sustained immune activation and tumor clearance in combination with proven immunotherapy strategies. Domvanalimab blocks TIGIT with sub-nanomolar affinity, and in a Phase 1 trial, demonstrated complete receptor coverage on all TIGIT-expressing peripheral leukocytes.
Domvanalimab exhibits a favorable safety profile and is now in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with zimberelimab (anti-PD-1) and etrumadenant (a dual A2a/A2b adenosine receptor antagonist).
A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.
A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.
A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab ± zimberelimab in participants with advanced solid malignancies.
